• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Logo
  • COVID-19 Resource Center
  • Categories
    • Feature
    • Cardiology trends
    • Cardiology research news
    • Conference coverage
    • Consensus reports & Position papers
    • Resources for Cardiology Professionals
    • COVID-19 Resource Center
  • Videos
  • Cardiology Best Practices

Cardiology Update

The latest trends and advancements made in cardiology research.

Global consensus on CTO-PCI best practices

November 7, 2019

Reading Time: 3 minutes

A chronic total occlusion (CTO) is the complete obstruction of a coronary artery, presenting a Thrombolysis In Myocardial Infarction (TIMI) 0 flow and an occlusion duration of at least 3 months. With the advancement of equipment, techniques and key indicators, the success rates of CTO percutaneous coronary intervention (PCI) have greatly improved. During CTO-PCI meetings in 2018, it was decided that the best practices surrounding this procedure should be made globally available. A total of 113 CTO-PCI experts from 56 countries were invited to participate in this collaboration.

7 key principles as best practices for CTO-PCI

  1. The primary indication for CTO-PCI is improving symptoms caused by myocardial ischemia. This has been shown in several observational studies and two randomized controlled clinical trials. The first was a single-center IMPACTOR-CTO trial involving 94 patients with isolated right coronary artery CTO. They were randomly assigned to CTO-PCI or optimal medical therapy only. The CTO-PCI cohort exhibited a significant reduction in ischemic burden at 12 months and improved 6-minute walking distance and quality of life.
  2. Dual angiography and detailed structured angiographic review is key for improving the technical success and reducing the CTO-PCI complications. This allows for clearer visualization of the CTO anatomy leading to increased understanding of lesion complexity and likelihood of success. There are 4 key angiographic parameters that must be assessed to plan CTO-PCI. This includes: the proximal cap, lesion length, course and composition, the distal vessel and collaterals.
  3. A microcatheter must be used for guidewire manipulation. There are many advantages to be gained by using a microcatheter. To name a few, it allows for rapid guidewire switching during both antegrade and retrograde wire manipulations. It improves both rotational and longitudinal guidewire movement precision within fluid or tissue. Finally, it allows the penetration force of the wire to be changed by modifying the distance between the guidewire tip and the microcatheter.
  4. There are 4 crossing strategies that are essential for successful CTO performance. They are classified according to wiring direction (antegrade versus retrograde) and whether the subintimal space is used. They include: antegrade wiring, antegrade dissection/reentry, retrograde wiring and retrograde dissection/reentry. While antegrade wiring is the most common, antegrade dissection/reentry involves entering the subintimal space and is often an unintended consequence of the former. In retrograde wiring, the occlusion is approached from the distal vessel and the guidewire advances against the flow of blood. Several algorithms are available to aide in crossing strategy selection, such as the hybrid, Asia Pacific and Euro-CTO. The decision is driven by the lesion characteristics in addition to the equipment availability and expertise.
  5. Adapting a new crossing strategy when progress has stalled is key for the success, safety and efficiency of CTO-PCI. When to administer a new strategy and which strategy to choose will depend on lesion characteristics, lessons learned from the original technique, available equipment and expertise. There can be many reasons to stop a CTO-PCI attempt. These include: high radiation dose, complication occurrence, large contrast volume administration, crossing failure or patient or physician fatigue. Indeed, flexibility is critical as initial crossing strategies have only proven successful in approximately 50% to 60% of CTOs.
  6. Dedicated CTO-PCI programs, continual physician training and rigorous outcome monitoring are associated with increased success rates. In comparison with non-CTO-PCI, there is an increased risk of complications. Having a skilled team is, therefore, even more critical. The average complication risk is approximately 3% but there is a large variation depending on the study and the lesion complexity.
  7. Optimal stent deployment is an often overlooked but critical parameter for successful CTO-PCI. Given the complexity and length of time required for CTO crossing, stent placement may seem more like an afterthought. However, multiple stents are often required during CTO-PCI in vessels that are calcified, diffusely diseased or negatively remodeled. Without proper care, restenosis and stent thrombosis may occur. Techniques such as intravascular imaging should be used to assess vessel size and calcification amount to aide in stent placement.

Goals and future direction for improved CTO-PCI outcomes

With these principles in place, the hope is to aide future training, improve clinical practice and overall education. The principles have already been implemented across many, experienced clinics. Those with less experience have consequently seen less optimal outcomes. This highlights the need for broader implementation as well as easy and safe CTO crossing and revascularization strategies.

For more Cardiology Update news, join us on Facebook, Twitter, LinkedIn or Instagram.

Author: Catherine Sorbara

Original Article: Circulation. 2019. 140:420-433


Check Out Related Articles

  • EuroPCR 2019: What you need to knowEuroPCR 2019: What you need to know
  • EXCEL trial: Repeat revascularization after CABG and PCI for left main diseaseEXCEL trial: Repeat revascularization after CABG and PCI for left main disease
  • TOP 15 CARDIOLOGY CONFERENCES FOR 2020TOP 15 CARDIOLOGY CONFERENCES FOR 2020

Primary Sidebar

Cardiology News Highlights

  • Facebook
  • Instagram
  • LinkedIn
  • Twitter

Most featured

Statin therapy: clinical benefits and potential risks

Statin therapies prevent both primary and secondary cardiovascular disease.However, long term safety … Continue Reading about Statin therapy: clinical benefits and potential risks

Cardiology Conferences 2021

Top Cardiology Conferences 2021

With the COVID-19 worldwide pandemic, conferences and congresses planned for 2020 converted to … Continue Reading about Top Cardiology Conferences 2021

N of 1 Trial - Statin side effects

SAMSON Trial: Role of nocebo effect in statin-associated muscle symptoms

The phenomenon of non-adherence to statin therapy is well known. Reasons for discontinuation include … Continue Reading about SAMSON Trial: Role of nocebo effect in statin-associated muscle symptoms

Browse by topic

Cardiac surgery Electrophysiology General cardiology Heart failure Imaging Interventional cardiology

Footer

Cardiology Update

Providing up-to-date developments in the field of cardiology in a clear and concise manner. All articles are written by professional medical journalists and subsequently reviewed by our editorial board. Cardiology Update provides breaking news, that matter to healthcare professionals in the field of cardiology. Subscribe for free to keep up with cardiology news updated regularly.

Learn More About Us

Contact Us

Recent

  • Top Cardiology Conferences 2021
  • SAMSON Trial: Role of nocebo effect in statin-associated muscle symptoms
  • Top 10 Highlights of AHA 2020 Congress
  • Thromboembolism in COVID-19 patients despite thromboprophylaxis
  • Top 10 highlights of TCT 2020 Congress

Search

Browse by topic

Cardiac surgery Electrophysiology General cardiology Heart failure Imaging Interventional cardiology

Terms & Conditions | Privacy | Disclaimer
© Clinicalinx B.V. All rights reserved. Postbus 2278, 1000 CG Amsterdam

We use cookies to provide the services and features offered on our website, and to improve our user experience. Learn more Ok
Privacy & Cookies Policy
Necessary Always Enabled